Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels

被引:91
作者
Lundeen, SG [1 ]
Carver, JM [1 ]
McKean, ML [1 ]
Winneker, RC [1 ]
机构
[1] WYETH AYERST RES, CARDIOVASC RES, PRINCETON, NJ 08852 USA
关键词
D O I
10.1210/en.138.4.1552
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Estrogens protect against cardiovascular disease in women through effects on the vascular wall and liver. Here we further characterize tile rat as a model for the evaluation of estrogenic effects on plasma lipid levels us. uterine wet weight. In adult ovariectomized female rats treated for 4 days sc, 17 alpha-ethinyl estradiol (EE) was the most potent agent to lower plasma total and high density lipoprotein cholesterol levels, followed by 17 beta-estradiol and 17 alpha-estradiol. However, 17 alpha-estradiol had the greatest separation of uterotropic us. cholesterol-lowering effects. EE had the same lipid-lowering potency whether administered sc ol orally to adult rats. It had no effect on cholesterol levels in immature rats, even though the uterotropic response was dramatic. Testosterone propionate, dexamethasone, and progesterone did not significantly lower cholesterol levels. The antiestrogens tamoxifen and raloxifene lowered cholesterol levels, but with less efficacy and potency than the estrogens. ICI 182780 had no effect on cholesterol levels. When coadministered with EE, ICI 182780 inhibited the cholesterol-lowering and uterotropic activities of EE, suggesting that the estrogen receptor pathway is involved. In conclusion, although the information from the rat is limited as a model of the low density lipoprotein-lowering effects of estrogens in humans, it can be used to study the effects and mechanism of action of estrogen and antiestrogens on plasma cholesterol levels.
引用
收藏
页码:1552 / 1558
页数:7
相关论文
共 38 条
[1]  
[Anonymous], 1988, Nonlinear regression analysis and its applications
[2]   ESTROGEN AND CORONARY HEART-DISEASE IN WOMEN [J].
BARRETTCONNOR, E ;
BUSH, TL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (14) :1861-1867
[3]   RALOXIFENE (LY139481 HCL) PREVENTS BONE LOSS AND REDUCES SERUM-CHOLESTEROL WITHOUT CAUSING UTERINE HYPERTROPHY IN OVARIECTOMIZED RATS [J].
BLACK, LJ ;
SATO, M ;
ROWLEY, ER ;
MAGEE, DE ;
BEKELE, A ;
WILLIAMS, DC ;
CULLINAN, GJ ;
BENDELE, R ;
KAUFFMAN, RF ;
BENSCH, WR ;
FROLIK, CA ;
TERMINE, JD ;
BRYANT, HU .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (01) :63-69
[4]  
Carroll R. J., 1988, TRANSFORMATION WEIGH
[5]  
CHAO Y, 1979, J BIOL CHEM, V254, P1360
[6]   BIOLOGIC EFFECTS OF TRANSDERMAL ESTRADIOL [J].
CHETKOWSKI, RJ ;
MELDRUM, DR ;
STEINGOLD, KA ;
RANDLE, D ;
LU, JK ;
EGGENA, P ;
HERSHMAN, JM ;
ALKJAERSIG, NK ;
FLETCHER, AP ;
JUDD, HL .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (25) :1615-1620
[7]   ORAL-CONTRACEPTIVES DECREASE HEPATIC CHOLESTEROL INDEPENDENT OF THE LDL RECEPTOR IN NONHUMAN-PRIMATES [J].
COLVIN, PL ;
WAGNER, JD ;
HEUSER, MD ;
SORCITHOMAS, MG .
ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (11) :1645-1649
[8]   COMPARISON OF TRANSDERMAL AND ORAL ESTROGEN-PROGESTIN REPLACEMENT THERAPY - EFFECTS ON SERUM-LIPIDS AND LIPOPROTEINS [J].
CROOK, D ;
CUST, MP ;
GANGAR, KF ;
WORTHINGTON, M ;
HILLARD, TC ;
STEVENSON, JC ;
WHITEHEAD, MI ;
WYNN, V .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (03) :950-955
[9]  
DONATI RJ, 1990, ARTERIOSCLEROSIS, V10, pA822
[10]  
DRAPER MW, 1994, CALCIFIED TISSUE INT, V54, P339